Search | Clinical Trials Finder

Conditions: Post Surgical Respiratory Failure, Respiratory Complication, Opioid Induced Respiratory Depression, Respiratory Arrest
Interventions: Linshom Continuous Predictive Respiratory Monitoring; Device
Lead sponsor: Linshom Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbus, Ohio

Conditions: Solid Tumor Malignancies
Interventions: Nivolumab, Pembrolizumab; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Westwood, Kansas

Conditions: Obesity
Interventions: Sibutramine; Behavioral
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 12 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: HIV-1-infection
Interventions: Mobile-enhanced Engagement Intervention; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 15 Years to 24 Years
Enrollment: 631 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure, Congestive Heart Failure
Interventions: Alexa+, Standard of Care Arm; Device · Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Endometriosis, Chronic Pelvic Pain, Dysmenorrhea
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 117
States / cities: Birmingham, Alabama • Decatur, Alabama • Fairhope, Alabama + 93 more

Conditions: Oropharyngeal Squamous Cell Carcinoma
Interventions: CUE-101; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
Interventions: Lutetium Lu 177-Edotreotide, Amino Acid Solution; Drug · Other
Lead sponsor: ITM Solucin GmbH; Industry
Eligibility: 24 Months to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 4
States / cities: San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Venous Leg Ulcer
Interventions: Wound Edge Debridement, Standard of Care Treatment; Procedure · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Stroke Hemorrhagic
Interventions: Surgical management, Medical Management; Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 19 more

Conditions: Prostate Cancer, Cancer of the PROSTATE, Prostatic Neoplasm
Interventions: Ultrasound guided prostate exam using SOC ultrasound system, mpMRI guided prostate examination using PI-RADS v2, High-resolution micro-ultrasound guided prostate biopsy; Device
Lead sponsor: Exact Imaging; Industry
Eligibility: 40 Years to 79 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Virginia Beach, Virginia

Conditions: Opioid-use Disorder
Interventions: OXD01 digital therapy, Standard of Care; Device · Other
Lead sponsor: Orexo AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Birmingham, Alabama • Oceanside, California • San Diego, California + 17 more

Conditions: Pain Catastrophizing, Pain, Chronic, Gender Identity
Interventions: Empowered Relief, Standard of Care; Behavioral · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: SARS-CoV-2
Interventions: Standard of Care (SOC) and Colchicine+Rosuvastatin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Bridgeport, Connecticut • Greenwich, Connecticut • New Haven, Connecticut + 1 more

Conditions: Colonic Neoplasms, Neoplasms, Colon
Interventions: Dostarlimab, CAPEOX, FOLFOX; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 49
States / cities: Tucson, Arizona • Los Angeles, California • New Haven, Connecticut + 31 more

Conditions: Pelvic Floor Disorder, Loneliness, Postpartum, Mental Health, Depression, Peritraumatic Distress, Women, Artificial Intelligence (AI), Chatbot
Interventions: Generative artificial intelligence (genAI) postpartum chatbot, Standard of Care (SOC); Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Sickle Cell Disease
Interventions: Voxelotor Only Product in Oral Dose Form, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 8 Years to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Sotorasib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Miami, Florida • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more

Conditions: Patient Adherence, HIV Seronegativity
Interventions: SoC + iTab; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 398 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 4
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 1 more

Conditions: Breast Cancer
Interventions: Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 176
States / cities: Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 139 more

Conditions: Lymphoma, Non-Hodgkin
Interventions: Standard of Care, JCAR017; Drug · Genetic
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 28
States / cities: Scottsdale, Arizona • San Francisco, California • Aurora, Colorado + 22 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Depemokimab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 1,196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 42
States / cities: Newport Beach, California • Lakewood, Colorado • Brandon, Florida + 35 more

Conditions: Breast Cancer
Interventions: Margin Probe, Control: Additional inspection; Device · Other
Lead sponsor: Dune Medical Devices; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 11
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Tampa, Florida + 7 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Ramucirumab, Pembrolizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Clinical Evaluation of an Alarm Activated Detection System to Enable Early Intervention of Emerging Respiratory Decline With the Linshom Medical Continuous Predictive Respiratory Sensor (CPRS)

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"

Providing Unique Support for Health (PUSH) Study

Personalized Voice Activated Wellness Assistants for Patients With Heart Failure

A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Due to Suspected or Confirmed Endometriosis and the Impact on the Disease or Symptom Progression.

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Developing Strategies for Effective Debridement in Patients for Venous Leg Ulcers

Rapid Evacuation and Access of Cerebral Hemorrhage Trial

Urology of Virginia Case Series

OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

Efficacy of a Chronic Pain Treatment Prior to Gender-affirming Surgery

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Postpartum Education Via Artificial Intelligence for Recovery and Loneliness: A Randomized Controlled Trial

Voxelotor Neurocognitive Function Study

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

MarginProbe® System U.S. Post-Approval Study

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma